Understanding the three-dimensional structure of biological targets is a fundamental pillar of modern drug discovery. This structure-based drug discovery approach allows researchers to visualize how potential drug molecules interact with their targets at the atomic level, providing critical insights for rational drug design and optimization. Historically, X-ray crystallography and Nuclear Magnetic Resonance (NMR) spectroscopy have been the primary tools for obtaining high-resolution structural information [Outside Information]. However, these techniques often face limitations when dealing with challenging targets such as large protein complexes, flexible molecules, or membrane proteins that are difficult to crystallize or express in sufficient quantities for NMR [Outside Information]. This is where cryo-electron microscopy (cryo-EM) has emerged as a revolutionary technology, significantly advancing the field of structural biology and, consequently, accelerating cryo em drug discovery, structure-based workflows.
Cryo-EM, particularly Single Particle Analysis (SPA), allows for the determination of high-resolution 3D structures of biological macromolecules in a state close to their native environment. This technique involves collecting extensive 2D images of purified macromolecular particles and using computational algorithms to process and reconstruct a detailed 3D structural model. The advantages of cryo-EM SPA are particularly relevant to drug discovery: it preserves samples close to their native state, can capture diverse conformations, requires minimal sample volume, and is capable of determining structures of heterogeneous protein complexes. These capabilities make cryo-EM an indispensable tool for tackling targets previously intractable by other methods.
Shuimu BioSciences, founded in 2017 at Tsinghua University, is a leading platform offering cryo-EM structure determination services. Their platform is equipped with state-of-the-art 300 kV cryo-EM instruments, with multiple machines located in both Beijing and Hangzhou, offering 24-hour instrument access for data acquisition. Leveraging deep research and technical heritage in structural biology, Shuimu has established efficient, advanced workflows for both experimental procedures and data analysis. Their commitment to quality and efficiency aims to enable faster structural determination.
To explore how cryo-EM can accelerate your structure-based drug discovery efforts, please visit https://shuimubio.com/.
Cryo-EM in Target Identification and Characterization
The initial stages of drug discovery involve identifying and validating suitable biological targets. Understanding the structure of these targets is crucial for designing molecules that can interact with them specifically and effectively. Cryo-EM plays a vital role here by providing detailed structural information about targets, especially those that are difficult to study using traditional methods.
Many important drug targets are membrane proteins, including G protein-coupled receptors (GPCRs), ion channels, and transporters. These proteins are often challenging to purify and crystallize for X-ray studies [Outside Information]. Cryo-EM excels at resolving the high-resolution structures of these membrane proteins, shedding light on ligand binding sites, receptor activation mechanisms, and signal transduction pathways. This structural information is crucial for developing antibodies or small molecules that target these proteins. Shuimu BioSciences has extensive experience in the production and purification method design of membrane proteins, including GPCRs, ion channels, and transport proteins, and has resolved structures of targets like GPR75, TRPV4, TRPML1, CYP51, ACE2, and various GPCRs and ion channels in published cases.
Beyond membrane proteins, cryo-EM is also used to analyze the structures of soluble proteins, enzymes, ribosomes, DNA and RNA structures, protein-nucleic acid complexes, and viral particles. Examples include enzymes like PolQ and C21, transcription complexes, viral capsid protein-RNA complexes, and various viruses like SARS-CoV-2, influenza virus, and African swine fever virus (ASFV). Obtaining high-resolution structures of these targets provides foundational knowledge for designing therapeutic interventions.
Before conducting high-resolution cryo-EM, initial sample assessment is often necessary. Negative staining electron microscopy provides a lower-cost method to quickly obtain low-resolution 2D projection images to assess sample particle size, uniformity, oligomeric state, morphology, and flexibility. Shuimu BioSciences offers negative staining services, including 2D analysis, which is useful for observing proteins, viruses, nanoparticles, and tissue sections. This initial characterization helps determine sample suitability for cryo-EM.
For specific particle types like Adeno-Associated Viruses (AAV), liposomes, Lipid Nanoparticles (LNPs), and Virus-Like Particles (VLPs), cryo-characterization using ultra-low temperature technology maintains the natural state of samples for observation and analysis. Shuimu's self-developed AI cryo-EM system, NanoSMART, can automatically identify features, analyze size distribution, roundness, and integrity, and provide detailed reports for these particles. This is particularly valuable for vaccine and gene therapy development, where understanding the morphology and integrity of viral vectors and delivery systems is critical.
To leverage structural insights for target identification and characterization in your research, discover Shuimu's capabilities at https://shuimubio.com/.
Analyzing Molecular Interactions in Structure-Based Drug Discovery
A key aspect of structure-based drug discovery is understanding how drug candidates bind to their targets. Cryo-EM provides a direct visual method to resolve the 3D structures of targets bound to small molecules, peptides, or antibodies. This allows researchers to pinpoint binding sites, analyze the interactions between specific amino acids and the drug molecule, and understand the conformational changes induced by binding.
For antibody drug development, cryo-EM is crucial for analyzing antibody-antigen complex structures. It reveals the high-resolution details of how antibodies recognize and bind to target antigens, providing insights into recognition mechanisms and binding sites. For instance, cryo-EM can show how a neutralizing antibody binds to a viral surface protein to prevent infection. Published cases supported by Shuimu's platform include structures of antibody-antigen complexes and studies of neutralizing antibodies against SARS-CoV-2 variants. Understanding these interactions structurally aids in the design of more effective antibody drugs with higher affinity and specificity. Cryo-EM also helps clarify the mechanism of action of antibody drugs, such as how they bind to targets and modulate signaling pathways.
Complementary techniques are often used alongside cryo-EM to characterize molecular interactions quantitatively. Surface Plasmon Resonance (SPR) and Bio-Layer Interferometry (BLI) are label-free techniques that monitor the binding and dissociation kinetics between biomolecules in real-time. SPR can analyze interactions between small molecule drugs and proteins, drug-antibody interactions, antigen-antibody interactions, and more. BLI is suitable for high-throughput protein interaction analysis, determining binding kinetics between proteins, nucleic acids, and even virus particles, and is valuable for determining the concentration and affinity of vaccines and antibodies. Shuimu BioSciences provides both SPR and BLI detection services, requiring specific sample purities, concentrations, and volumes. These techniques provide essential data on binding strength (affinity, Kd) and speed (kinetics), which, combined with structural insights from cryo-EM, offer a comprehensive understanding of drug-target interactions vital for cryo em drug discovery, structure-based approaches.
Learn more about how Shuimu BioSciences can support your molecular interaction studies at https://shuimubio.com/.
Cryo-EM in Lead Optimization
Once initial drug candidates (leads) are identified, the process moves to lead optimization, aiming to improve properties such as potency, selectivity, solubility, and pharmacokinetic profile [Outside Information]. Structural information obtained through cryo-EM is invaluable during this stage of structure-based drug discovery. By analyzing the high-resolution structure of the target bound to a lead compound, researchers can identify specific interactions that contribute to binding and design modified compounds with improved properties.
Cryo-EM allows for the visualization of dynamic processes and conformational changes that occur during binding, which can inform the design of lead candidates with enhanced affinity and specificity. For antibody drugs, structural analysis of existing leads using cryo-EM can reveal potential areas for improvement and support epitope mapping and antibody engineering efforts. The high resolution and efficiency of cryo-EM data acquisition contribute to accelerating the optimization process.
While cryo-EM SPA is powerful for large macromolecules and complexes, Micro-electron diffraction (MicroED) is a cutting-edge cryo-EM related technique specifically suited for determining high-resolution structures from microcrystals and nanocrystals, particularly for organic compounds and small molecule drugs. Shuimu BioSciences excels in providing accurate structural insights for small molecule samples, peptides, and protein crystals using MicroED technology. MicroED can resolve structures of challenging small molecules and even peptides and proteins at very high resolutions, sometimes reaching 0.6-1.0Å. Shuimu's proprietary eTasED software integrates MicroED into conventional cryo-EM systems, enhancing efficiency. This capability is crucial for optimizing small molecule leads, providing atomic-level detail about their conformation and interaction with targets.
To optimize your lead compounds with structural precision, explore the cryo-EM and MicroED services at https://shuimubio.com/.
Supporting Services for Cryo-EM Drug Discovery
Successful cryo-EM structural analysis relies heavily on high-quality protein samples. Shuimu BioSciences provides a complete protein expression and purification platform to minimize variability and standardize the entire pipeline, aiming to provide "One-Stop" solutions from gene sequences to high-resolution 3D structures.
Their protein expression systems cover Prokaryotic (E. coli) and Eukaryotic (Yeast Cells, Insect Cells, Mammalian Cells) options, each offering specific advantages depending on the protein characteristics and requirements. The mammalian system is preferred for producing therapeutic proteins, vaccines, and antibodies due to its intrinsic post-translational modification functions, resulting in proteins closest to their natural state. The insect cell system is suitable for expressing eukaryotic proteins and toxic proteins with post-translational modifications. E. coli is economical and fast, suitable for simple eukaryotic and prokaryotic proteins. A cell-free system is also available for rapid protein synthesis in vitro. Shuimu has extensive experience, particularly with challenging membrane proteins.
Protein purification processes available include affinity chromatography, ion-exchange chromatography, gel filtration, and reverse-phase HPLC (RP-HPLC). Protein quality control is performed using techniques like SDS-PAGE, Western blot, mass spectrometry, thermal stability, and solubility testing. These upstream services ensure that samples meet the high purity and homogeneity requirements for cryo-EM.
For samples that present challenges such as severe preferred orientation, high background noise, or small molecular weight, Shuimu has developed a series of graphene support grids, GraFuture™, offering a potential solution to overcome these limitations during sample preparation for cryo-EM.
For a comprehensive approach to cryo em drug discovery, structure-based research, including essential upstream services, visit https://shuimubio.com/.
Shuimu BioSciences: Expertise and Capabilities in Cryo-EM Drug Discovery
Shuimu BioSciences positions itself as the world's largest commercial cryo-EM platform, boasting eight 300 kV instruments available for data acquisition (2 in Beijing, 6 in Hangzhou). They have extensive experience, with over 400 completed cryo-EM projects and more than 150 structures resolved. This includes resolving structures as small as 51 kDa and achieving impressive resolutions, with a best resolution of 1.8 Å reported, and a groundbreaking resolution of 1.4 Å mentioned for some cases.
Their team comprises PhD-level experts specializing in structural biology, protein science, and computational biology from preeminent institutions. They are equipped with cutting-edge instrumentation, including high-performance detectors, energy filters, spherical aberration, and phase plates, ensuring imaging quality. The platform emphasizes daily maintenance and upkeep, guaranteeing efficiency and quality of data collection, with instruments maintaining over 330 days of available machine time annually and an annual fault-free operation rate greater than 97%.
Shuimu also leverages proprietary AI algorithms and software suites like SMART and NanoSMART to streamline cryo-EM data analysis, reduce machine runtime and required data volume, and improve efficiency and accuracy in structure determination and particle characterization. Their MicroED service, supported by the eTasED software, also demonstrates a strong track record with over 80% of projects successfully delivered and high resolutions achieved.
This combination of a large, well-maintained platform, experienced team, advanced technology (including AI and specialized grids like GraFuture), and a strong track record makes Shuimu BioSciences a powerful partner for cryo em drug discovery, structure-based research. They offer efficient, accurate, and comprehensive solutions from sample preparation through to high-resolution structure determination and analysis.
To partner with a leader in cryo-EM for your drug discovery programs, visit https://shuimubio.com/.
Case Studies and Successful Projects
Shuimu BioSciences's platform has supported numerous research results published in top international journals, resolving atomic-level resolution structures covering a wide range of biological samples relevant to drug discovery, including ion channels, GPCRs, antigen-antibody complexes, and SARS-CoV-2 proteins.
For example, their work has contributed to resolving the cryo-EM structure of the human GluN1-GluN2A subtype NMDA receptor bound with different small molecules. They have also been involved in studies determining the structure of the human histamine H1 receptor/Gq complex. In the field of antibody therapeutics, they supported studies resolving structures of SARS-CoV-2 neutralizing antibodies, providing insights for cocktail design against variants. The platform has also contributed to resolving structures of SARS-CoV-2 spike protein in complex with ACE2 receptors, crucial for understanding viral entry and informing vaccine and antibody design. Other published work includes structural insights into adhesion GPCRs, Nav1.7 gating modulation, chemokine receptors CCR2 and CCR3, and various other protein targets, demonstrating their broad capability in supporting diverse structure-based drug discovery projects.
These successful cases underscore Shuimu's technical expertise and its ability to provide critical structural data for complex biological systems, directly supporting advancements in vaccine development, antibody therapeutics, and the discovery of small molecule drugs.
Review the breadth of Shuimu's successful projects and how they can support your specific research needs at https://shuimubio.com/.
Conclusion
Cryo-EM has become an indispensable tool in cryo em drug discovery, structure-based approaches, offering unprecedented capabilities for resolving the structures of challenging drug targets and their complexes with potential therapeutic molecules. From understanding the fundamental structure and function of targets to analyzing detailed molecular interactions and guiding lead optimization, cryo-EM provides critical insights that accelerate the drug development pipeline.
Shuimu BioSciences stands at the forefront of this field, providing a comprehensive suite of services that span protein preparation and analysis, advanced cryo-EM structure determination (SPA), MicroED for small molecules, negative staining, and specialized cryo-characterization for particles like LNPs and VLPs. Their large-scale platform, experienced team, cutting-edge technology, proprietary AI software, and proven track record make them a powerful partner for researchers and pharmaceutical companies engaged in structure-based drug discovery. By offering "One-Stop" solutions from gene to structure, Shuimu minimizes logistical hurdles and standardizes processes, enabling efficient and high-quality structural biology support. As the technology continues to evolve, cryo-EM will undoubtedly play an even greater role in tackling complex diseases and accelerating the discovery of novel therapeutics.
To learn more about how Shuimu BioSciences can support your cryo em drug discovery, structure-based projects and leverage the power of high-resolution structural information, visit https://shuimubio.com/ today.